NASDAQ · SNY
Sanofi ADS
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for SNY: Oct 30, 2026
Sanofi ADS is expected to report earnings on 10/30/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $1.63. The reported EPS for the same quarter last year was $1.7.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $1.63 | $1.75 | $1.53 | 4 |
| Dec 2026 | $1.07 | $1.20 | $0.97 | 3 |
| Mar 2027 | $1.14 | $1.18 | $1.10 | 2 |
| Jun 2027 | $1.29 | $1.35 | $1.23 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel · Zacks · The Motley Fool- RTTNews · Oct 29, 12:26 PM EDTNovavax Gains $125 Mln Payment As Sanofi Begins Phase 3 Combination Vaccine Trial; Stock Up(RTTNews) – Novavax, Inc. (NVAX) said it has earned a $125 million milestone payment following the initiation of Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial in Europe, which is evaluating its COVID-19 vaccine Nuvaxovid.
- RTTNews · Oct 29, 4:01 AM EDTBiotech Stocks Facing FDA Decision In November 2026(RTTNews) – The FDA's November calendar has more than a dozen PDUFA dates on the horizon, setting the stage for an eventful month in the regulatory landscape.
- Fintel · Oct 26, 8:23 AM EDTSanofi Breaks Ground on New Insulin Manufacturing Facility in GermanySanofi has broken ground on a new insulin manufacturing facility at its BioCampus in Frankfurt, Germany. The new facility will be built on a 36,000-square-meter footprint, equivalent to approximately five football fields. Designed to meet the highest standards of quality and auto
- RTTNews · Oct 23, 10:53 AM EDTWeekly Buzz: AZN, ALVO Score FDA Nod; EYPT Cuts Jobs; RHHBY, GEHC Enter Deal; VERA Posts Trial Win(RTTNews) – Healthcare and biotech news this week centred on regulatory approvals, strategic deals, and pivotal clinical data.
- RTTNews · Oct 20, 12:00 PM EDTTeva, Sanofi Report Sustained Duvakitug Benefits In Phase 2b IBD Study(RTTNews) – Teva Pharmaceutical Industries Ltd. (TEVA) and Sanofi (SNY) announced positive long-term Phase 2b data for investigational duvakitug, showing sustained improvements in ulcerative colitis (UC) and Crohn's disease (CD) through Week 44 of the RELIEVE UCCD long-term exten
- Zacks · Oct 20, 9:25 AM EDTGSK's New Drugs and Pipeline Hold the Key to Long-Term GrowthGSK's newer drugs, expanding indications and promising pipeline could drive long-term growth, with sales expected to exceed 40 billion pounds by 2031.
- RTTNews · Oct 19, 9:34 AM EDTSanofi Commences Construction Of Insulin Facility In Frankfurt, Germany(RTTNews) – Monday, Sanofi (SNY) commenced construction of a new state-of-the-art insulin manufacturing facility at its BioCampus in Frankfurt, Germany, leveraging advanced digital technologies and artificial intelligence across manufacturing and quality processes.
- The Motley Fool · Oct 17, 3:44 PM EDTForget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit ShareRegeneron’s revenue is growing at a good clip despite declining Eylea sales.
- RTTNews · Oct 16, 2:46 AM EDTSanofi, PCPA Sign LOI For Dupixent Across Four Additional Indications(RTTNews) – Sanofi (SNY) said Thursday it has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) and signed a letter of intent, or LOI for Dupixent across four additional indications in dermatology and respiratory.
- Zacks · Oct 15, 11:31 AM EDTCan Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?NKTR advances rezpeg into phase III studies for atopic dermatitis, with additional autoimmune indications offering potential growth amid stiff competition.
- RTTNews · Oct 15, 10:55 AM EDTRecursion To Receive $10 Mln Milestone Payment As Sanofi Selects Immunology Drug Candidate(RTTNews) – Recursion Pharmaceuticals Inc. (RXRX) announced Thursday that Sanofi (SNY) has selected the first development candidate under their research collaboration, triggering a $10 million milestone payment to Recursion.
- Zacks · Oct 14, 11:09 AM EDTWhich Pharma Stock Looks More Attractive: Sanofi or AbbVie?Sanofi's upgraded 2026 outlook, Dupixent growth and attractive valuation give it an edge over AbbVie, despite pipeline setbacks and vaccine sales challenges.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Sanofi ADS from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.